Business Context and Reporting Period
Company: Alkermes Plc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 29, 2023
Reporting Period: Event-based report regarding a material definitive agreement entered into on August 29, 2023.
Key Financial Metrics
This filing is a current report regarding a legal settlement and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Agreements
Settlement Agreement: On August 29, 2023, Alkermes entered into a Confidential Settlement and License Agreement with Teva Pharmaceuticals USA, Inc. to resolve patent litigation concerning Alkermes' product VIVITROL (naltrexone for extended-release injectable suspension). The litigation involved U.S. Patent No. 7,919,499 and Teva's Abbreviated New Drug Application (ANDA) No. 213195.
- License Terms: Alkermes granted Teva a non-exclusive, royalty-free, non-transferable, and non-sublicensable limited license.
- Scope: Teva may make, have made, use, import, sell, and offer for sale its product in the United States.
- Effective Date: The license becomes effective on January 15, 2027, or earlier under certain circumstances.
- Legal Action: The parties are obligated to file a joint Stipulated Consent Judgment and Injunction to dismiss pending proceedings.
Guidance, Outlook, and Risks
Regulatory Review: The Settlement Agreement is subject to review by the U.S. Federal Trade Commission (FTC) and the U.S. Department of Justice (DOJ).
Disclosure: A press release announcing the agreement was issued on August 30, 2023. The full text of the Settlement Agreement is intended to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending September 30, 2023.
Unusual Items: The filing notes that the description of the agreement in this 8-K is not complete and is qualified by reference to the full agreement.
Investor Verification Checklist
- Verify the final terms of the Confidential Settlement and License Agreement once filed as an exhibit to the Q3 2023 Form 10-Q.
- Monitor the status of the review by the U.S. FTC and DOJ, as the agreement is subject to their approval.
- Assess the potential financial impact of the royalty-free license effective January 15, 2027, on future VIVITROL revenue projections.
- Review the August 30, 2023 press release (Exhibit 99.1) for additional management commentary not included in the 8-K summary.